Skip to main content
Clinical Trials/CTRI/2010/091/000571
CTRI/2010/091/000571
Not yet recruiting
Phase 3

Evaluation of Efficacy and Safety of a Sustained release vs. Immediate release Mucoregulator for the treatment of bronchial asthma: An open label, randomized, comparative, multi-centric trial.

Sun Pharmaceutical Industries Ltd.0 sites200 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Sun Pharmaceutical Industries Ltd.
Enrollment
200
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Male or female Patients aged between 18 and 65 years.
  • 2\.Patients with history of bronchial asthma and chronic obstructive pulmonary disease as defined by American Thoracic Society (ATS).
  • 3\.Baseline FEV1 50 ? 85% in patients either untreated or receiving e.g. short\-acting bronchodilators.
  • 4\.No change in the asthma treatment 4 weeks prior to baseline period
  • 5\.Patients willing to give informed consent.

Exclusion Criteria

  • 1\.Pregnant or lactating women and women of childbearing potential who are not using contraceptives.
  • 2\.Patients with infection of lower airways.
  • 3\.Patients with cancer, pulmonary tuberculosis, or acute infection, Myocardial infarction, low blood pressure.
  • 4\.Patients who were hospitalized for asthma within three month before the study.
  • 5\.Patients suffering from lung disease other than asthma and COPD.
  • 6\.Patients who had used systemic steroid prior to 4 week of baseline visit and who are taking long acting \&\#946;\-agonist, inhaled anticholinergics with in one month before study and cromolyn, nedocromil within two week before study.
  • 7\.Patients who were heavy smokers with \> 10 pack\-years.
  • 8\.Patients with any severe illness like liver insufficiency, active hepatitis, known infection with HIV etc.
  • 9\.Patients with history of non\-compliance to medical regimens or those patients unwilling to comply with the study protocol.
  • 10\.Patients with suspected hypersensitivity and/or contraindication to any ingredients of the study medication or rescue medications.

Outcomes

Primary Outcomes

Not specified

Similar Trials